The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients

摘要: Background/Aims Response to HCV treatment with pegylated interferon-α is variable but might at least in part depend on genetic host factors. The G protein β3 unit (GNB3) C825T polymorphism has been shown affect response mono-infection. Here, we analyzed the impact of GNB3 genotype context HCV/HIV co-infection. Methods HIV/HCV co-infected (n = 112) and mono-infected patients (n = 150), receiving therapy IFN-α/ribavirin, were enrolled into this study. Furthermore, 220 healthy 92 HIV patients. was defined correlated respect response. Results distribution differed significantly between HIV-positive/HCV-negative (p = 0.0002) or controls (p = 0.03). Patients a CC had lower SVR rates as compared carriers non-CC (52% versus 77%; p = 0.018). In logistic regression analysis associated (p = 0.018). contrast patients, did not Conclusions 825 poor This underlines factors for